Triterpenes in cancer: significance and their influence

Molecular Biology Reports

Volumn 43, Issue 9, 2016, Pages 881-896

  Gill, Balraj Singh ^a   Kumar, Sanjeev ^a   Navgeet, ^b  

^a CENTRAL UNIVERSITY OF PUNJAB   (India)

^b HMV College Jalandhar   (India)

Author keywords

Clinical trials; Ganoderma lucidum; PI3K Akt mTOR pathway; Receptor tyrosine kinase; Triterpenes

Indexed keywords

ACETYL 11 KETO BETA BOSWELLIC ACID; ANTINEOPLASTIC AGENT; ASIATIC ACID; BETULIC ACID; CELASTROL; ERYTHRODIOL; ESCULENTOSIDE; FUNGAL EXTRACT; GLYCYRRHIZIC ACID; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; LUPEOL; MAMMALIAN TARGET OF RAPAMYCIN; MASLINIC ACID; MEMBRANE RECEPTOR; NATURAL PRODUCT; OLEANOLIC ACID; PHOSPHATIDYLINOSITOL 3 KINASE; PLANT MEDICINAL PRODUCT; PLATYCODIN D; PRISTIMERIN; PROTEIN KINASE B; SAIKOSAPONIN A; STAT3 PROTEIN; TOLL LIKE RECEPTOR; TRITERPENE DERIVATIVE; TUMOR NECROSIS FACTOR; UNCLASSIFIED DRUG; UNINDEXED DRUG; URSOLIC ACID; UVAOL; WITHANOLIDE; TRITERPENE;

ANTIINFLAMMATORY ACTIVITY; APOPTOSIS; AZADIRACHTA INDICA; BIOLOGICAL FUNCTIONS; CUCURBITA PEPO; DRUG EFFICACY; DRUG STRUCTURE; DRUG TARGETING; GANODERMA LUCIDUM; GANODERMA TSUGAE; HUMAN; IMMUNOMODULATION; MALIGNANT NEOPLASTIC DISEASE; NONHUMAN; REVIEW; SIGNAL TRANSDUCTION; TUMOR VASCULARIZATION; ANIMAL; CLINICAL TRIAL (TOPIC); METABOLISM; NEOPLASMS;

ANIMALS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; CLINICAL TRIALS AS TOPIC; HUMANS; NEOPLASMS; SIGNAL TRANSDUCTION; TRITERPENES;

EID: 84976276835     PISSN: 03014851     EISSN: 15734978     Source Type: Journal    
DOI: 10.1007/s11033-016-4032-9     Document Type: Review

References (114)

1. Croce CM (2008) Oncogenes and cancer. N Engl J Med 358:502–511
2. Anand SS, Gill BS (2015) Breakthroughs in epigenetics. PharmaTutor 3:16–24
3. Negi A, Ramarao P, Kumar R (2013) Recent advancements in small molecule inhibitors of insulin-like growth factor-1 receptor (IGF-1R) tyrosine kinase as anticancer agents. Mini Rev Med Chem 13:653–681
4. Zwick E, Bange J, Ullrich A (2001) Receptor tyrosine kinase signalling as a target for cancer intervention strategies. Endocr Relat Cancer 8:161–173
5. Lemmon MA, Schlessinger J (2010) Cell signaling by receptor tyrosine kinases. Cell 141:1117–1134
6. Schlessinger J (2000) Cell signaling by receptor tyrosine kinases. Cell 103:211–225
7. Negi A, Gill B, Anand SS (2014) Tilling: versatile reverse genetic tool. PharmaTutor 2:26–32
8. Joshi G, Singh PK, Negi A, Rana A, Singh S, Kumar R (2015) Growth factors mediated cell signalling in prostate cancer progression: implications in discovery of anti-prostate cancer agents. Chem Biol Interact 240:120–133
9. Negi A, Gill B (2013) Success Stories of enolate form of drugs. PharmaTutor 1:45–53
10. Pezzuto JM (1997) Plant-derived anticancer agents. Biochem Pharmacol 53:121–133
11. Reynolds KA, Wallace KK, Handa S, Brown MS, McArthur HA, Floss HG (1997) Biosynthesis of the shikimate-derived starter unit of the immunosuppressant ascomycin: stereochemistry of the 1,4-conjugate elimination. J Antibiot 50:701–703
12. Yang H, Dou QP (2010) Targeting apoptosis pathway with natural terpenoids: implications for treatment of breast and prostate cancer. Curr Drug Targets 11:733
13. Yin M-C (2012) Anti-glycative potential of triterpenes: a mini-review. BioMedicine 2:2–9
14. Liby KT, Yore MM, Sporn MB (2007) Triterpenoids and rexinoids as multifunctional agents for the prevention and treatment of cancer. Nat Rev Cancer 7:357–369
15. Jäger S, Trojan H, Kopp T, Laszczyk MN, Scheffler A (2009) Pentacyclic triterpene distribution in various plants–rich sources for a new group of multi-potent plant extracts. Molecules 14:2016–2031
16. Liang PH, Ko TP, Wang AHJ (2002) Structure, mechanism and function of prenyltransferases. Eur J Biochem 269:3339–3354
17. Bublil EM, Yarden Y (2007) The EGF receptor family: spearheading a merger of signaling and therapeutics. Curr Opin Cell Biol 19:124–134
18. Singh P, Alex JM, Bast F (2014) Insulin receptor (IR) and insulin-like growth factor receptor 1 (IGF-1R) signaling systems: novel treatment strategies for cancer. Med Oncol 31:1–14
19. Landman GW, Kleefstra N, van Hateren KJ, Groenier KH, Gans RO, Bilo HJ (2010) Metformin associated with lower cancer mortality in type 2 diabetes ZODIAC-16. Diabetes Care 33:322–326
20. Kelleher FC, O’Sullivan H, Smyth E, McDermott R, Viterbo A (2013) Fibroblast growth factor receptors, developmental corruption and malignant disease. Carcinogenesis. doi:10.1093/carcin/bgt254
21. Yadav VR, Prasad S, Sung B, Kannappan R, Aggarwal BB (2010) Targeting inflammatory pathways by triterpenoids for prevention and treatment of cancer. Toxins 2:2428–2466
22. Kuruvilla FG, Schreiber SL (1999) The PIK-related kinases intercept conventional signaling pathways. Chem Biol 6:R129–R136
23. Peltier J, O’Neill A, Schaffer DV (2007) PI3K/Akt and CREB regulate adult neural hippocampal progenitor proliferation and differentiation. Dev Neurobiol 67:1348–1361
24. Gill BS, Alex JM, Kumar S (2016) Missing link between microRNA and prostate cancer. Tumor Biol. doi:10.1007/s13277-016-4900-x
25. Dienstmann R, Rodon J, Serra V, Tabernero J (2014) Picking the point of inhibition: a comparative review of PI3K/AKT/mTOR pathway inhibitors. Mol Cancer Therapeut 13:1021–1031
26. Whitman M, Downes CP, Keeler M, Keller T, Cantley L (1988) Type I phosphatidylinositol kinase makes a novel inositol phospholipid, phosphatidylinositol-3-phosphate. Nature 332:644–646
27. Carpenter C, Duckworth B, Auger K, Cohen B, Schaffhausen B, Cantley L (1990) Purification and characterization of phosphoinositide 3-kinase from rat liver. J Biol Chem 265:19704–19711
28. Lawlor MA, Alessi DR (2001) PKB/Akt a key mediator of cell proliferation, survival and insulin responses? J Cell Sci 114:2903–2910
29. Andjelkovic M, Alessi DR, Meier R, Fernandez A, Lamb NJ, Frech M, Cron P, Cohen P, Lucocq JM, Hemmings BA (1997) Role of translocation in the activation and function of protein kinase B. J Biol Chem 272:31515–31524
30. Alessi DR, James SR, Downes CP, Holmes AB, Gaffney PR, Reese CB, Cohen P (1997) Characterization of a 3-phosphoinositide-dependent protein kinase which phosphorylates and activates protein kinase Bα. Curr Biol 7:261–269
31. J-i Okano, Gaslightwala I, Birnbaum MJ, Rustgi AK, Nakagawa H (2000) Akt/protein kinase B isoforms are differentially regulated by epidermal growth factor stimulation. J Biol Chem 275:30934–30942
32. Yang P-C, Yang C-H, Huang C-C, Hsu K-S (2008) Phosphatidylinositol 3-kinase activation is required for stress protocol-induced modification of hippocampal synaptic plasticity. J Biol Chem 283:2631–2643
33. Paez J, Sellers WR (2004) PI3K/PTEN/Akt pathway. In: Frank DA (ed) Signal transduction in cancer. Springer, Berlin, pp 145–167
34. Mamane Y, Petroulakis E, Rong L, Yoshida K, Ler LW, Sonenberg N (2004) eIF4E—from translation to transformation. Oncogene 23:3172–3179
35. Pommier Y, Sordet O, Antony S, Hayward RL, Kohn KW (2004) Apoptosis defects and chemotherapy resistance: molecular interaction maps and networks. Oncogene 23:2934–2949
36. Astrinidis A, Henske EP (2005) Tuberous sclerosis complex: linking growth and energy signaling pathways with human disease. Oncogene 24:7475–7481
37. Ruggero D, Pandolfi PP (2003) Does the ribosome translate cancer? Nat Rev Cancer 3:179–192
38. Liu J-P (1999) Studies of the molecular mechanisms in the regulation of telomerase activity. FASEB J 13:2091–2104
39. Hay N, Sonenberg N (2004) Upstream and downstream of mTOR. Genes Dev 18:1926–1945
40. Guertin DA, Sabatini DM (2007) Defining the role of mTOR in cancer. Cancer Cell 12:9–22
41. Jacinto E, Loewith R, Schmidt A, Lin S, Rüegg MA, Hall A, Hall MN (2004) Mammalian TOR complex 2 controls the actin cytoskeleton and is rapamycin insensitive. Nat Cell Biol 6:1122–1128
42. Kundu M (2014) Too sweet for autophagy: hexokinase inhibition of mTORC1 activates autophagy. Mol Cell 53:517–518
43. Page C, Lin H, Jin Y, Castle V, Nunez G, Huang M, Lin J (1999) Overexpression of Akt/AKT can modulate chemotherapy-induced apoptosis. Anticancer Res 20:407–416
44. Friedrichs WE, Russell DH, Donzis EJ, Middleton AK, Silva JM, Roth RA, Hidalgo M (2004) Inhibition of mTOR activity restores tamoxifen response in breast cancer cells with aberrant Akt activity. Clin Cancer Res 10:8059–8067
45. Bjornsti M-A, Houghton PJ (2004) The TOR pathway: a target for cancer therapy. Nat Rev Cancer 4:335–348
46. Beuvink I, Boulay A, Fumagalli S, Zilbermann F, Ruetz S, O’Reilly T, Natt F, Hall J, Lane HA, Thomas G (2005) The mTOR inhibitor RAD001 sensitizes tumor cells to DNA-damaged induced apoptosis through inhibition of p21 translation. Cell 120:747–759
47. Gill BS, Kumar S (2015) Differential algorithms-assisted molecular modeling-based identification of mechanistic binding of ganoderic acids. Med Chem Res 24:3483–3493
48. McConkey DJ, Zhu K (2008) Mechanisms of proteasome inhibitor action and resistance in cancer. Drug Resist Update 11:164–179
49. Rios J, Recio M, Escandell J, Andujar I (2009) Inhibition of transcription factors by plant-derived compounds and their implications in inflammation and cancer. Curr Pharm Des 15:1212–1237
50. Alghasham AA (2013) Cucurbitacins—a promising target for cancer therapy. Int J Health Sci 7:77–89
51. Klampfer L (2006) Signal transducers and activators of transcription (STATs): novel targets of chemopreventive and chemotherapeutic drugs. Curr Cancer Drug Targets 6:107–121
52. Catlett-Falcone R, Landowski TH, Oshiro MM, Turkson J, Levitzki A, Savino R, Ciliberto G, Moscinski L, Fernández-Luna JL, Nuñez G (1999) Constitutive activation of Stat3 signaling confers resistance to apoptosis in human U266 myeloma cells. Immunity 10:105–115
53. Mora LB, Buettner R, Seigne J, Diaz J, Ahmad N, Garcia R, Bowman T, Falcone R, Fairclough R, Cantor A (2002) Constitutive activation of STAT3 in human prostate tumors and cell lines direct inhibition of STAT3 signaling induces apoptosis of prostate cancer cells. Cancer Res 62:6659–6666
54. Duncan MD, Duncan KL (1997) Cucurbitacin E targets proliferating endothelia. J Surg Res 69:55–60
55. Escandell JM, Recio MC, Máñez S, Giner RM, Cerdá-Nicolás M, Ríos JL (2007) Cucurbitacin R reduces the inflammation and bone damage associated with adjuvant arthritis in Lewis rats by suppression of tumor necrosis factor-α in T lymphocytes and macrophages. J Pharmacol Exp Ther 320:581–590
56. Pathak AK, Bhutani M, Nair AS, Ahn KS, Chakraborty A, Kadara H, Guha S, Sethi G, Aggarwal BB (2007) Ursolic acid inhibits STAT3 activation pathway leading to suppression of proliferation and chemosensitization of human multiple myeloma cells. Mol Cancer Res 5:943–955
57. Hersh EM, Metch BS, Muggia FM, Brown TD, Whitehead RP, Budd GT, Rinehart JJ, Crawford ED, Bonnet JD, Behrens BC (1991) Phase II studies of recombinant human tumor necrosis factor alpha in patients with malignant disease: a summary of the Southwest Oncology Group experience. J Immunother 10:426–431
58. Schneider P, Thome M, Burns K, Bodmer J-L, Hofmann K, Kataoka T, Holler N, Tschopp J (1997) TRAIL receptors 1 (DR4) and 2 (DR5) signal FADD-dependent apoptosis and activate NF-κB. Immunity 7:831–836
59. Wajant H, Pfizenmaier K, Scheurich P (2003) Tumor necrosis factor signaling. Cell Death Differ 10:45–65
60. Herbst RS, Eckhardt SG, Kurzrock R, Ebbinghaus S, O’Dwyer PJ, Gordon MS, Novotny W, Goldwasser MA, Tohnya TM, Lum BL (2010) Phase I dose-escalation study of recombinant human Apo2L/TRAIL, a dual proapoptotic receptor agonist, in patients with advanced cancer. J Clin Oncol 28:2839–2846
61. Spierings DC, de Vries EG, Timens W, Groen HJ, Boezen HM, de Jong S (2003) Expression of TRAIL and TRAIL death receptors in stage III non-small cell lung cancer tumors. Clin Cancer Res 9:3397–3405
62. O’Neill L (2002) Signal transduction pathways activated by the IL-1 receptor/toll-like receptor superfamily. In: Wagner H, Beutler B (eds) Toll-like receptor family members and their ligands. Springer, Berlin, pp 47–61
63. Akira S, Takeda K (2004) Toll-like receptor signalling. Nat Rev Immunol 4:499–511
64. Shivakumar SB, Bharti D, Subbarao RB, Jang SJ, Park JS, Ullah I, Park JK, Byun JH, Park BW, Rho GJ (2016) DMSO-and serum-free cryopreservation of Wharton’s jelly tissue isolated from human umbilical cord. J Cell Biochem. doi:10.1002/jcb.25563
65. Gill B, Sharma P, Kumar R, Kumar S (2015) Misconstrued versatility of Ganoderma lucidum: a key player in multi-targeted cellular signaling. Tumor Biol 37:2789–2804
66. Meier P, Silke J (2003) Programmed cell death: superman meets Dr Death. Nat Cell Biol 5:1035–1038
67. Chu W-M (2013) Tumor necrosis factor. Cancer Lett 328:222–225
68. Ferrara N, Kerbel RS (2005) Angiogenesis as a therapeutic target. Nature 438:967–974
69. Folkman J (1995) Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat Med 1:27–30
70. Safayhi H, Sailer E (1997) Anti-inflammatory actions of pentacyclic triterpenes. Planta Med 63:487–493
71. Sánchez-Quesada C, López-Biedma A, Gaforio JJ (2015) Maslinic acid enhances signals for the recruitment of macrophages and their differentiation to m1 state. Evid Based Complement Altern Med. doi:10.1155/2015/654721
72. Shyu K-G, Tsai S-C, Wang B-W, Liu Y-C, Lee C-C (2004) Saikosaponin C induces endothelial cells growth, migration and capillary tube formation. Life Sci 76:813–826
73. Y-x Zhou, Y-l Huang (2009) Antiangiogenic effect of celastrol on the growth of human glioma: an in vitro and in vivo study. Chin Med J 122:1666–1673
74. Kimura Y, Taniguchi M, Baba K (2001) Antitumor and antimetastatic effects on liver of triterpenoid fractions of Ganoderma lucidum: mechanism of action and isolation of an active substance. Anticancer Res 22:3309–3318
75. Takada Y, Aggarwal BB (2003) Betulinic acid suppresses carcinogen-induced NF-κB activation through inhibition of IκBα kinase and p65 phosphorylation: abrogation of cyclooxygenase-2 and matrix metalloprotease-9. J Immunol 171:3278–3286
76. Chintharlapalli S, Papineni S, Ramaiah SK, Safe S (2007) Betulinic acid inhibits prostate cancer growth through inhibition of specificity protein transcription factors. Cancer Res 67:2816–2823
77. Hsu Y-L, Kuo P-L, Lin L-T, Lin C-C (2005) Asiatic acid, a triterpene, induces apoptosis and cell cycle arrest through activation of extracellular signal-regulated kinase and p38 mitogen-activated protein kinase pathways in human breast cancer cells. J Pharm Exp Ther 313:333–344
78. Yun K-J, Kim J-Y, Kim J-B, Lee K-W, Jeong S-Y, Park H-J, Jung H-J, Cho Y-W, Yun K, Lee K-T (2008) Inhibition of LPS-induced NO and PGE 2 production by asiatic acid via NF-κB inactivation in RAW 264.7 macrophages: possible involvement of the IKK and MAPK pathways. Int Immunopharmacol 8:431–441
79. Zhou C, Liu W, He W, Wang H, Chen Q, Song H (2015) Saikosaponin a inhibits RANKL-induced osteoclastogenesis by suppressing NF-κB and MAPK pathways. Int Immunopharmacol 25:49–54
80. Pang X, Yi Z, Zhang X, Sung B, Qu W, Lian X, Aggarwal BB, Liu M (2009) Acetyl-11-keto-β-boswellic acid inhibits prostate tumor growth by suppressing vascular endothelial growth factor receptor 2-mediated angiogenesis. Cancer Res 69:5893–5900
81. Takada Y, Ichikawa H, Badmaev V, Aggarwal BB (2006) Acetyl-11-keto-β-boswellic acid potentiates apoptosis, inhibits invasion, and abolishes osteoclastogenesis by suppressing NF-κB and NF-κB-regulated gene expression. J Immunol 176:3127–3140
82. Pang X, Yi Z, Zhang J, Lu B, Sung B, Qu W, Aggarwal BB, Liu M (2010) Celastrol suppresses angiogenesis-mediated tumor growth through inhibition of AKT/mammalian target of rapamycin pathway. Cancer Res 70:1951–1959
83. Kim Y, Kang H, Jang S-W, Ko J (2010) Celastrol inhibits breast cancer cell invasion via suppression of NF-κB-mediated matrix metalloproteinase-9 expression. Cell Physiol Biochem Int J Exp Cell Physiol Biochem Pharmacol 28:175–184
84. Weng C-J, Yen G-C (2010) The in vitro and in vivo experimental evidences disclose the Chemopreventive effects of Ganoderma lucidum on cancer invasion and metastasis. Clin Exp Metastasis 27:361–369
85. Thoennissen NH, Iwanski GB, Doan NB, Okamoto R, Lin P, Abbassi S, Song JH, Yin D, Toh M, Xie WD (2009) Cucurbitacin B induces apoptosis by inhibition of the JAK/STAT pathway and potentiates antiproliferative effects of gemcitabine on pancreatic cancer cells. Cancer Res 69:5876–5884
86. Zha Q-B, Zhang X-Y, Lin Q-R, Xu L-H, Zhao G-X, Pan H, Zhou D, Ouyang D-Y, Liu Z-H, He X-H (2015) Cucurbitacin e induces autophagy via downregulating mTORC1 signaling and upregulating AMPK activity. PLoS One 10(5):e0124355. doi:10.1371/journal.pone.0124355
87. Ichikawa H, Takada Y, Shishodia S, Jayaprakasam B, Nair MG, Aggarwal BB (2006) Withanolides potentiate apoptosis, inhibit invasion, and abolish osteoclastogenesis through suppression of nuclear factor-κB (NF-κB) activation and NF-κB-regulated gene expression. Mol Cancer Ther 5:1434–1445
88. Subramanian C, White P, Gingrich A, Timmermann BN, Cohen MS (2015) Abstract B24: natural withanolides: A new group of anticancer drugs that selectively target the PI3K-mTOR pathway as novel potent therapeutics against colon cancers in vitro and in vivo. Mol Cancer Ther 14:B24–B24
89. Saleem M, Kaur S, Kweon M-H, Adhami VM, Afaq F, Mukhtar H (2005) Lupeol, a fruit and vegetable based triterpene, induces apoptotic death of human pancreatic adenocarcinoma cells via inhibition of Ras signaling pathway. Carcinogenesis 26:1956–1964
90. Saleem M, Afaq F, Adhami VM, Mukhtar H (2004) Lupeol modulates NF-κB and PI3K/Akt pathways and inhibits skin cancer in CD-1 mice. Oncogene 23:5203–5214
91. Mu X, Shi W, Sun L, Li H, Jiang Z, Zhang L (2012) Pristimerin, a triterpenoid, inhibits tumor angiogenesis by targeting VEGFR2 activation. Molecules 17:6854–6868
92. Li D-M, Guo Y-K, Li Q, Zhang J, Wang X-J, Bai J-G (2012) The pretreatment of cucumber with methyl jasmonate regulates antioxidant enzyme activities and protects chloroplast and mitochondrial ultrastructure in chilling-stressed leaves. Sci Horticult 143:135–143
93. Ahn KS, Hahn B-S, Kwack K, Lee EB, Kim YS (2006) Platycodin D-induced apoptosis through nuclear factor-κB activation in immortalized keratinocytes. Eur J Pharmacol 537:1–11
94. Ogasawara R, Sato K, Higashida K, Nakazato K, Fujita S (2013) Ursolic acid stimulates mTORC1 signaling after resistance exercise in rat skeletal muscle. Am J Physiol Endocrinol Metab 305:E760–E765
95. Xu Y-H, Zhao L-J, Li Y (2009) Alisol B acetate induces apoptosis of SGC7901 cells via mitochondrial and phosphatidylinositol 3-kinases/Akt signaling pathways. World J Gastroenterol WJG 15:2870
96. 2+ ATPase pump, induces autophagy, endoplasmic reticulum stress, and apoptosis. Mol Cancer Ther 9:718–730
97. Elumalai P, Arunkumar R, Benson CS, Sharmila G, Arunakaran J (2014) Nimbolide inhibits IGF-I-mediated PI3K/Akt and MAPK signalling in human breast cancer cell lines (MCF-7 and MDA-MB-231). Cell Biochem Funct 32:476–484
98. Menegazzi M, Di Paola R, Mazzon E, Genovese T, Crisafulli C, Dal Bosco M, Zou Z, Suzuki H, Cuzzocrea S (2008) Glycyrrhizin attenuates the development of carrageenan-induced lung injury in mice. Pharmacol Res 58:22–31
99. He S-Q, Gao M, Fu Y-F, Zhang Y-N (2015) Glycyrrhizic acid inhibits leukemia cell growth and migration via blocking AKT/mTOR/STAT3 signaling. Int J Clin Exp Pathol 8:5175
100. Kuo H-P, Hsu S-C, Ou C-C, Li J-W, Tseng H-H, Chuang T-C, Liu J-Y, Chen S-J, Su M-H, Cheng Y-C (2013) Ganoderma tsugae extract inhibits growth of HER2-overexpressing cancer cells via modulation of HER2/PI3K/Akt signaling pathway. Evid Based Complement Altern Med. doi:10.1155/2013/219472
101. Baselga J, Swain SM (2009) Novel anticancer targets: revisiting ERBB2 and discovering ERBB3. Nat Rev Cancer 9:463–475
102. Li Y, Li T, Miao C, Li J, Xiao W, Ma E (2013) β-Eudesmol induces JNK-dependent apoptosis through the mitochondrial pathway in HL60 cells. Phytother Res 27:338–343
103. Wang Y-Y, Lv Y-F, Lu L, Cai L (2014) Oridonin inhibits mTOR signaling and the growth of lung cancer tumors. Anticancer Drugs 25:1192–1200
104. Maurya S, Devi S, Pandey V, Khosa R (1989) Content of betulin and betulinic acid, antitumor agents of Zizyphus species. Fitoterapia 60:468–469
105. Sánchez-Quesada C, López-Biedma A, Warleta F, Campos M, Beltrán G, Gaforio JJ (2013) Bioactive properties of the main triterpenes found in olives, virgin olive oil, and leaves of Olea europaea. J Agric Food Chem 61:12173–12182
106. Reyes-Zurita FJ, Rufino-Palomares EE, Lupiáñez JA, Cascante M (2009) Maslinic acid, a natural triterpene from Olea europaea L., induces apoptosis in HT29 human colon-cancer cells via the mitochondrial apoptotic pathway. Cancer Lett 273:44–54
107. Huang L, Guan T, Qian Y, Huang M, Tang X, Li Y, Sun H (2011) Anti-inflammatory effects of maslinic acid, a natural triterpene, in cultured cortical astrocytes via suppression of nuclear factor-kappa B. Eur J Pharmacol 672:169–174
108. Martín R, Ibeas E, Carvalho-Tavares J, Hernández M, Ruiz-Gutierrez V, Nieto ML (2009) Natural triterpenic diols promote apoptosis in astrocytoma cells through ROS-mediated mitochondrial depolarization and JNK activation. PLoS One 4:e5975
109. Lu J, D-m Wu, Zheng Y-l HuB, Cheng W, Z-f Zhang, Shan Q (2011) Ursolic acid improves high fat diet-induced cognitive impairments by blocking endoplasmic reticulum stress and IκB kinase β/nuclear factor-κB-mediated inflammatory pathways in mice. Brain Behav Immun 25:1658–1667
110. C-t Tu, Li J, F-p Wang, Li L, J-y Wang, Jiang W (2012) Glycyrrhizin regulates CD4+ T cell response during liver fibrogenesis via JNK, ERK and PI3K/AKT pathway. Int Immunopharmacol 14:410–421
111. Xiao Z-Y, Zheng Q-Y, Jiang Y-Y, Zhou B, Yin M, Wang H-B, Zhang J-P (2004) Effects of esculentoside A on production of interleukin-1, 2, and prostaglandin E ~ 2. Acta Pharmacol Sin 25:817–821
112. Jiang J, Slivova V, Harvey K, Valachovicova T, Sliva D (2004) Ganoderma lucidum suppresses growth of breast cancer cells through the inhibition of Akt/NF-κB signaling. Nutr Cancer 49:209–216
113. Chen N-H, Liu J-W, Zhong J-J (2010) Ganoderic acid T inhibits tumor invasion in vitro and in vivo through inhibition of MMP expression. Pharmacol Rep 62:150–163
114. Weng C-J, Chau C-F, Hsieh Y-S, Yang S-F, Yen G-C (2008) Lucidenic acid inhibits PMA-induced invasion of human hepatoma cells through inactivating MAPK/ERK signal transduction pathway and reducing binding activities of NF-κB and AP-1. Carcinogenesis 29:147–156